Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phosphate Sandoz is an oral mineral supplement containing sodium acid phosphate anhydrous as its active ingredient. It is primarily used to treat hypercalcaemia associated with conditions such as hyperparathyroidism and malignancy, as well as hypophosphataemia linked to vitamin D-resistant rickets and vitamin D-resistant hypophosphataemic osteomalacia. By replenishing systemic phosphate levels, the drug helps restore calcium-phosphate homeostasis and can modulate the circadian rhythm of parathyroid hormone (PTH) and bone turnover markers. It is formulated as an effervescent tablet that is dissolved in water before oral administration. In clinical research, it has been evaluated for its effects on bone metabolism in postmenopausal women with reduced bone mineral density.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium acid phosphate.